Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature sugge...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Adv
Main Authors: Han, Se young, Mrózek, Krzysztof, Voutsinas, Jenna, Wu, Qian, Morgan, Elizabeth A., Vestergaard, Hanne, Ohgami, Robert, Kluin, Philip M., Kristensen, Thomas Kielsgaard, Pullarkat, Sheeja, Møller, Michael Boe, Schiefer, Ana-Iris, Baughn, Linda B., Kim, Young, Czuchlewski, David, Hilberink, Jacobien R., Horny, Hans-Peter, George, Tracy I., Dolan, Michelle, Ku, Nam K., Arana Yi, Cecilia, Pullarkat, Vinod, Kohlschmidt, Jessica, Salhotra, Amandeep, Soma, Lori, Bloomfield, Clara D., Chen, Dong, Sperr, Wolfgang R., Marcucci, Guido, Cho, Christina, Akin, Cem, Gotlib, Jason, Broesby-Olsen, Sigurd, Larson, Melissa, Linden, Michael A., Deeg, H. Joachim, Hoermann, Gregor, Perales, Miguel-Angel, Hornick, Jason L., Litzow, Mark R., Nakamura, Ryotaro, Weisdorf, Daniel, Borthakur, Gautam, Huls, Gerwin, Valent, Peter, Ustun, Celalettin, Yeung, Cecilia C. S.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2021
נושאים:
Myeloid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8152510/
https://ncbi.nlm.nih.gov/pubmed/34003250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003605
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים